A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Neurology

• Publication date

  1998-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/WNL.50.3.645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurological and Neuropsychiatric Manifestations of HIV-1 Infection

  1998cited by this paper
• Changes in policy for publishing manuscripts in Neurology

  1997cited by this paper
• Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

  1997cited by this paper
• l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro

  1997cited by this paper
• APOPTOTIC NEURONS IN BRAINS FROM PEDIATRIC PATIENTS WITH HIV-1 ENCEPHALITIS AND PROGRESSIVE ENCEPHALOPATHY

  1996cited by this paper
• Modulation of gene expression rather than monoamine oxidase inhibition

  1996cited by this paper
• (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.

  1996cited by this paper
• Neuronal apoptosis in HIV infection in adults

  1995cited by this paper
• Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users.

  1995cited by this paper
• Effect of MPTP and l‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain

  1995cited by this paper
• Dementia Associated with the Acquired Immunodeficiency Syndrome

  1995cited by this paper
• (-)Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain.

  1994cited by this paper
• Increased CNTF gene expression in process‐bearing astrocytes following injury is augmented by R(−)‐deprenyl

  1994cited by this paper
• The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease

  1994cited by this paper
• Glia of the Cholinergic Electromotor Nucleus of Torpedo Are the Source of the cDNA Encoding a GAT‐1‐Like GABA Transporter

  1994cited by this paper
• Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity.

  1994cited by this paper
• The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes.

  1994cited by this paper
• (−)‐Deprenyl Reduces PC12 Cell Apoptosis by Inducing New Protein Synthesis

  1994cited by this paper
• Effects of the ANF-C receptor ligand des[Cys105,Cys121]rANF(104-126) on ANF internalization and cGMP production by bovine pulmonary artery endothelial cells.

  1994cited by this paper
• Neurotrophins in neurodegenerative disease: theoretical issues and clinical trials.

  1994cited by this paper
• Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms

  1993cited by this paper
• Dementia in AIDS patients

  1993cited by this paper
• Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo.

  1993cited by this paper
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

  1993cited by this paper
• Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition

  1993cited by this paper
• Neurological involvement in Wegener's granulomatosis: An analysis of 324 consecutive patients at the Mayo Clinic

  1993cited by this paper
• The diagnosis of thoracic aortic dissection by noninvasive imaging procedures.

  1993cited by this paper
• Oxidative stress, glutamate, and neurodegenerative disorders.

  1993cited by this paper
• Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial

  1993cited by this paper
• Presentation and course of AIDS dementia complex: 10 years of follow‐up in Amsterdam, The Netherlands

  1993cited by this paper
• Selegiline can mediate neuronal rescue rather than neuronal protection

  1993cited by this paper
• GABA in pancreatic islets: metabolism and function.

  1992cited by this paper
• Dihydrolipoic acid--a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals.

  1992cited by this paper
• Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection

  1991cited by this paper
• Computerized and conventional neuropsychological assessment of HIV‐1‐infected homosexual men

  1991cited by this paper
• Normative Data for a Brief Neuropsychological Screening Battery

  1991cited by this paper
• On the production of neurologists in the United States

  1991cited by this paper
• Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding.

  1988cited by this paper
• Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.

  1988cited by this paper
• What price success? The continuing saga of the toxic:therapeutic ratio in the use of aminoglycoside antibiotics.

  1988cited by this paper
• Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

  1987cited by this paper
• Recent Developments in Parkinson's Disease

  1986cited by this paper
• The AIDS dementia complex: I. Clinical features

  1986cited by this paper
• Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature.

  1985cited by this paper
• The CES-D Scale

  1977cited by this paper
• Assessment of older people: self-maintaining and instrumental activities of daily living.

  1969cited by this paper
• STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

  1963cited by this paper

• An Overview of HIV-associated Neurocognitive Disorder in South Africa

  2025cites this paper
• Central Nervous System Complications of HIV in Children

  2024cites this paper
• Virus infection participates in the occurrence and development of human diseases through monoamine oxidase

  2023cites this paper
• Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

  2021influential citation
• HIV Associated Neurocognitive Disorders Subsidence Through Citalopram Addition in Anti-retroviral Therapy (HANDS-CARE): A Concept Note

  2021cites this paper
• Naturally Occurring Antioxidants

  2020cites this paper
• Bayesian Model Infers Drug Repurposing Candidates for Treatment of COVID-19

  2020cites this paper
• Cognitive disorders in people living with HIV.

  2020cites this paper
• Dopaminergic impact of cART and anti-depressants on HIV Neuropathogenesis in older adults.

  2019cites this paper
• Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review

  2019cites this paper
• Gene Delivery of Antioxidant Enzymes in HIV-1-Associated Neurocognitive Disorder

  2018cites this paper
• Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review

  2018cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial

  2017cites this paper
• HTLV-1 Associated Neurological Disorders.

  2017cites this paper
• HIV-Associated Neurocognitive Disorders

  2017cites this paper
• Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls

  2016cites this paper
• 127 – Neurologic Diseases Caused by Human Immunodeficiency Virus Type 1 and Opportunistic Infections

  2015cites this paper
• Oxidative Stress, Micronutrients, and HIV Dementia

  2015cites this paper
• Cognitive impairment in patients with AIDS – prevalence and severity

  2015cites this paper
• Primary psychiatric conditions associated with cognitive impairment Delirium Prevalence and severity in HIV infection and AIDS

  2015cites this paper
• Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant Enzymes

  2014cites this paper
• Adjuvant therapies for HIV-associated neurocognitive disorders

  2014cites this paper
• Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity

  2014cites this paper
• Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.

  2014cites this paper
• Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development

  2013cites this paper
• Rivastigmine for HIV-associated neurocognitive disorders

  2013cites this paper
• HIV-Associated Neurological Disorders

  2012cites this paper
• HIV treatment: mechanisms of neurotoxicity and implications for targeted therapy

  2012cites this paper
• The Role of Adaptive Stress Responses in HIV Replication and Macrophage-Mediated Neurotoxicity

  2011cites this paper
• HIV-1 infection and cognitive impairment in the cART era: a review.

  2011cites this paper
• HIV-associated neurocognitive disorders: a changing pattern

  2011cites this paper
• NeuroAIDS: An Evolving Epidemic

  2009cites this paper
• HIV-related neurocognitive impairment in the HAART era

  2009cites this paper
• Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy

  2009cites this paper
• Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains

  2009cites this paper
• Adjunctive Therapy for Long-Term Support of Cognitive Impairment

  2009cites this paper
• HIV-1-Associated Neurocognitive Disorders in the HAART Era

  2009cites this paper
• Antioxidants and Brain Function in HIV/AIDS

  2009cites this paper
• 19 Pathogenesis and Treatment of HIV-associated Dementia: Recent Studies in a SCID Mouse Model

  2009cites this paper
• Acetyl-L-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?

  2008cites this paper
• [Clinical features and course of 5 cases with HIV encephalopathy].

  2008cites this paper
• Adjunctive therapies for AIDS dementia complex.

  2008cites this paper
• HIV infection of the central nervous system: clinical features and neuropathogenesis.

  2008cites this paper
• Human immunodeficiency virus-associated dementia: clinical aspects, biology, and treatment.

  2008cites this paper
• Primary Neurological Manifestation of HIV/AIDS

  2008cites this paper
• Insulin, Insulin-Like Growth Factors and Incretins

  2008cites this paper
• Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090

  2007cites this paper
• Selegiline transdermal system: current awareness and promise.

  2007cites this paper
• The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System

  2007cites this paper
• HIV Dementia: A Neurodegenerative Disorder with Viral Etiology

  2007cites this paper
• A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

  2007cites this paper
• Neuropharmacology of HIV/AIDS.

  2007cites this paper
• Oxidative Stress and Therapeutic Approaches in HIV Dementia

  2006cites this paper
• Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl.

  2006cites this paper
• Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities

  2006cites this paper
• Regulation of neural cell survival by HIV-1 infection.

  2006cites this paper
• Alpha-Lipoic Acid Alpha-lipoic Acid

  2006cites this paper
• The AIDS dementia complex: Clinical and basic Neuroscience with implications for novel molecular therapies

  2005cites this paper
• R-Form Alpha-Lipoic Acid Monograph prepared

  2005cites this paper
• HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations.

  2005cites this paper
• Inflammation and Neuroaxonal Injury in Multiple Sclerosis and AIDS Dementia Complex: Implications for Neuroprotective Treatment

  2005cites this paper
• CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.

  2004cites this paper
• Alpha lipoic acid for dementia.

  2004cites this paper
• Monoamine oxidase inhibition and CNS immunodeficiency infection.

  2004cites this paper
• Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity

  2004cites this paper
• Whole-brain N-acetylaspartate level and cognitive performance in HIV infection.

  2003cites this paper
• Neuroinflammation-Mediated Neurotoxin Production in Neurodegenerative Diseases

  2003cites this paper
• Neurologic aspects of HIV infection in infants and children: Therapeutic approaches and outcome

  2003cites this paper
• HIV meningitis and dementia

  2003cites this paper
• Human immunodeficiency virus-associated dementia: An evolving disease

  2003cites this paper
• Chapter 18 – Neurologic Complications of HIV and AIDS

  2003cites this paper
• Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment

  2003cites this paper
• Progress in Clinical Neurosciences: The Neuropathogenesis of HIV Infection: Host-Virus Interaction and the Impact of Therapy

  2002cites this paper
• Involvement of dopamine in the progression of AIDS Dementia Complex

  2002cites this paper
• Dopamine Is a Pathogenetic Factor in HIV-Induced Neuro-AIDS

  2002cites this paper
• Parkinsonism in HIV dementia

  2002cites this paper
• Pharmacological Interventions in Aging and Age‐associated Disorders

  2002cites this paper
• Neuroinflammation-Mediated Neurotoxin Production in Neurodegenerative Diseases: Potential of Nitrones as Therapeutics

  2002cites this paper
• The pathogenesis of HIV-induced dementia.

  2002cites this paper
• Correlation between percentage of brain parenchymal volume and neurocognitive performance in HIV-infected patients.

  2002cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Role of Free Radicals in the Neurodegenerative Diseases

  2001cites this paper
• Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia.

  2001cites this paper
• Neurobehavioral Complications of HIV Infection

  2001cites this paper
• Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection.

  2001cites this paper
• Immunopathogenesis of HIV-associated dementia

  2001cites this paper
• Apoptosis in HIV disease pathogenesis

  2001cites this paper
• Predictors of perception of cognitive functioning in HIV/AIDS.

  2000cites this paper
• Pharmacological frontiers in the treatment of AIDS dementia

  2000cites this paper
• HIV-1–Associated Cognitive-Motor Disorders: A Research-Based Approach to Diagnosis and Treatment

  2000cites this paper
• HIV dementia: the role of the basal ganglia and dopaminergic systems

  2000cites this paper
• Diagnosis and treatment of HIV-associated neurocognitive disorders.

  2000cites this paper
• Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study

  2000cites this paper
• Of mice and men

  2000cites this paper
• Human immunodeficiency virus-associated dementia.

  2000cites this paper
• Antioxidant therapy in neurologic disease.

  2000cites this paper
• Randomized trial of the platelet-activating factor antagonist lexipafant in HIV–associated cognitive impairment

  1999cites this paper
• Central neurologic complications of HIV infection

  1999cites this paper
• Antioxidants, Oxidative Stress, and Degenerative Neurological Disorders (44448)

  1999cites this paper